Design and Methods

BACKGROUND AND OBJECTIVES The aim of this study was to evaluate the incidence and outcome of invasive fungal infections (IFI) in patients with hematologic malignancies. DESIGN AND METHODS This was a retrospective cohort study of patients admitted between 1999 and 2003 to 18 hematology wards in Italy. Each participating center provided information on all patients with newly diagnosed hematologic malignancies admitted during the survery period and on all episodes of IFI experienced by these patients. RESULTS The cohort was formed of 11,802 patients with hematologic malignacies: acute leukemia (myeloid 3012, lymphoid 1173), chronic leukemia (myeloid 596, lymphoid 1104), lymphoma (Hodgkin's 844, non-Hodgkin's 3457), or multiple myeloma (1616). There were 538 proven or probable IFI (4.6%); 373 (69%) occurred in patients with acute myeloid leukemia. Over half (346/538) were caused by molds (2.9%), in most cases Aspergillus spp. (310/346). The 192 yeast infections (1.6%) included 175 cases of candidemia. Overall and IFI-attributable mortality rates were 2% (209/11802) and 39% (209/538), respectively. The highest IFI-attributable mortality rates were associated with zygomycosis (64%) followed by fusariosis (53%), aspergillosis (42%), and candidemia (33%). INTERPRETATION AND CONCLUSIONS Patients with hematologic malignancies are currently at higher risk of IFI caused by molds than by yeasts, and the incidence of IFI is highest among patients with acute myeloid leukemia. Aspergillus spp are still the most common pathogens, followed by Candida spp. Other agents are rare. The attributable mortality rate for aspergillosis has dropped from 60-70% to approximately 40%. Candidemia-related mortality remains within the 30-40% range reported in literature although the incidence has decreased.

[1]  J. Baddley,et al.  Epidemiology of Aspergillus terreus at a University Hospital , 2003, Journal of Clinical Microbiology.

[2]  L. Mele,et al.  Retrospective study of candidemia in patients with hematological malignancies. Clinical features, risk factors and outcome of 76 episodes , 1999, European journal of haematology.

[3]  D. Denning,et al.  Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[4]  L. Mele,et al.  Pneumocystis carinii pneumonia in patients with malignant haematological diseases: 10 years' experience of infection in GIMEMA centres , 2002, British journal of haematology.

[5]  Sungching C Glenn,et al.  Invasive Fungal Infections in Pediatric Oncology Patients: 11-Year Experience at a Single Institution , 2005, Journal of pediatric hematology/oncology.

[6]  B. Lebeau,et al.  Candidemia in cancer patients: a prospective, multicenter surveillance study by the Invasive Fungal Infection Group (IFIG) of the European Organization for Research and Treatment of Cancer (EORTC). , 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[7]  J. Baddley,et al.  Invasive mold infections in allogeneic bone marrow transplant recipients. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[8]  L. Mele,et al.  The epidemiology of fusariosis in patients with haematological diseases. Gimema Infection Programme. , 2000, British journal of haematology.

[9]  M. Okudaira,et al.  Increase in aspergillosis and severe mycotic infection in patients with leukemia and MDS: Comparison of the data from the Annual of the Pathological Autopsy Cases in Japan in 1989, 1993 and 1997 , 2003, Pathology international.

[10]  L. Pagano,et al.  Mucormycosis in hematologic patients. , 2004, Haematologica.

[11]  A. Favero,et al.  Infections caused by filamentous fungi in patients with hematologic malignancies. A report of 391 cases by GIMEMA Infection Program. , 2001, Haematologica.

[12]  D. Denning,et al.  Practice Guidelines for Diseases Caused by Aspergillus , 2000 .

[13]  S J Lin,et al.  Aspergillosis case-fatality rate: systematic review of the literature. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[14]  Russell E. Lewis,et al.  Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases. , 2005, The Journal of infectious diseases.

[15]  F. Marty,et al.  Breakthrough zygomycosis after voriconazole treatment in recipients of hematopoietic stem-cell transplants. , 2004, The New England journal of medicine.

[16]  M G Rinaldi,et al.  Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole. , 1991, The New England journal of medicine.

[17]  J. Sobel,et al.  Practice guidelines for the treatment of candidiasis. Infectious Diseases Society of America. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[18]  L. Mele,et al.  The epidemiology of fusariosis in patients with haematological diseases , 2000 .

[19]  S. Brunet,et al.  Risk of reactivation of a recent invasive fungal infection in patients with hematological malignancies undergoing further intensive chemo-radiotherapy. A single-center experience and review of the literature. , 1997, Haematologica.

[20]  R. Wenzel,et al.  Current trends in the epidemiology of nosocomial bloodstream infections in patients with hematological malignancies and solid neoplasms in hospitals in the United States. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[21]  D. Snydman,et al.  The changing face of candidemia: emergence of non-Candida albicans species and antifungal resistance. , 1996, The American journal of medicine.

[22]  J. Sobel,et al.  Practice guidelines for the treatment of candidiasis. Infectious Diseases Society of America. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[23]  L. Pagano,et al.  Cryptococcosis in patients with hematologic malignancies. A report from GIMEMA-infection. , 2004, Haematologica.

[24]  E. Thiel,et al.  Improved Outcome of Zygomycosis in Patients with Hematological Diseases? , 2004, Leukemia & lymphoma.

[25]  J. Enders,et al.  Infectious Diseases Society of America. , 1969, Antimicrobial agents and chemotherapy.

[26]  T. C. White,et al.  Candidemia in allogeneic blood and marrow transplant recipients: evolution of risk factors after the adoption of prophylactic fluconazole. , 2000, The Journal of infectious diseases.

[27]  C. Maslo,et al.  Epidemiology of invasive aspergillosis in France: a six-year multicentric survey in the Greater Paris area. , 2002, The Journal of hospital infection.

[28]  K. Mühlemann,et al.  Risk factors for invasive aspergillosis in neutropenic patients with hematologic malignancies , 2005, Leukemia.

[29]  H. Prince,et al.  Fatal disseminated infection by Scedosporium prolificans during induction therapy for acute leukemia: a case report and literature review. , 1999, Pathology.

[30]  C. Solano,et al.  Invasive fungal infections after allogeneic peripheral blood stem cell transplantation: incidence and risk factors in 395 patients , 2002, British journal of haematology.

[31]  L. Pagano,et al.  Invasive Infections Caused by Trichosporon Species and Geotrichum capitatum in Patients with Hematological Malignancies: a Retrospective Multicenter Study from Italy and Review of the Literature , 2005, Journal of Clinical Microbiology.

[32]  M. Nucci,et al.  Risk factors and attributable mortality associated with superinfections in neutropenic patients with cancer. , 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[33]  E. Anaissie,et al.  Fusarium infection in hematopoietic stem cell transplant recipients. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[34]  D. Denning,et al.  Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[35]  V. Anttila,et al.  Invasive fungal infections in autologous stem cell transplant recipients: a nation‐wide study of 1188 transplanted patients , 2004, European journal of haematology.

[36]  J. Perfect,et al.  Comparison of caspofungin and amphotericin B for invasive candidiasis. , 2002, The New England journal of medicine.

[37]  Y. Kanda,et al.  Effect of fluconazole prophylaxis on fungal blood cultures: an autopsy‐based study involving 720 patients with haematological malignancy , 2002, British journal of haematology.

[38]  Lawrence Corey,et al.  Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[39]  D. Kontoyiannis,et al.  Breakthrough Candidemia in Patients with Cancer Differs from De Novo Candidemia in Host Factors and Candida Species But Not Intensity , 2002, Infection Control & Hospital Epidemiology.

[40]  M. Montagna,et al.  Fungemia in acute leukemia patients: a single institution's experience. , 2004, The new microbiologica.

[41]  D. Denning,et al.  Practice guidelines for diseases caused by Aspergillus. Infectious Diseases Society of America. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[42]  William R. Kirkpatrick,et al.  Invasive Aspergillosis Disease Spectrum, Treatment Practices, and Outcomes , 2000, Medicine.

[43]  A. Favero,et al.  Fatal haemoptysis in pulmonary filamentous mycosis: an underevaluated cause of death in patients with acute leukaemia in haematological complete remission. A retrospective study and review of the literature , 1995, British journal of haematology.

[44]  M. Schuster,et al.  Posaconazole as Salvage Therapy for Zygomycosis , 2006, Antimicrobial Agents and Chemotherapy.

[45]  Richard Sylvester,et al.  Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. , 2002, The New England journal of medicine.